Publications

Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: Potential human-to-animal transmission. by Seguin JC, Walker RD, Caron JP, Kloos WE, George CG, Hollis RJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 1999; 37 (5): 1459-1463

Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. by Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA and Jones RN published in J. Clin. Microbiol. 1999; 37 (9): 2987-2991

Bacterial pathogens isolated from patients with bloodstream infections in Latin America, 1997: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. by Sader HS, Pfaller MA, Jones RN, Doern GV, Gales AC, Winokur PL and Kugler KC published in Braz. J. Infect. Dis. 1999; 3 (3): 97-110

Results of the 1997 SENTRY Antimicrobial Surveillance Program in three Brazilian medical centers. by Sader HS, Sampaio JL, Zoccoli C and Jones RN published in Braz. J. Infect. Dis. 1999; 3 (2): 63-79

Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. by Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME and Hajjeh RA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 217-222

Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. by Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, and Beach ML published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 283-297

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). by Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S and Hollis RJ published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 19-25

Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group. by Pfaller MA, Korten V, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 65-73

Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela: Comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (2): 153-158

Multicenter evaluation of antimicrobial resistance to six broad- spectrum β-lactams in Colombia: Comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN, Doern GV and Salazar JC published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 235-241

Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe). by Odland BA, Jones RN, Verhoef J, Fluit A and Beach ML published in Diagn. Microbiol. Infect. Dis. 1999; 34 (4):315-320

Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/Etest method evaluations and quality control guidelines. The Quality Control Study Group. by Marshall SA, Jones RN, and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (1): 19-25

Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health. by Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (3): 181-186

Ability of the modified Vitek card to detect coagulase-negative staphylococcal with mec A and oxacillin-resistant phenotypes. by Marshall SA, Pfaller MA and Jones RN published in J. Clin. Microbiol. 1999; 37 (6): 2122-2123

Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. by Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (8): 2005-2009

In vitro evaluation of cefepime and other broad-spectrum β-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group. by Lewis MT, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 285-290

In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: A phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. by Lewis MT, Yamaguchi K, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 307-315

In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: Role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group. by Lewis MT, Biedenbach DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 317-323

Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. by Kugler KC, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 73-76

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds. by Jones RN, Low DE and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 101-112

Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-µg) diffusion methods. The Quality Control Study Group. by Jones RN, Kugler KC, Erwin ME, Biedenbach DJ, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 247-253

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and Etest method validation. Quality Control Study Group. by Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 91-98

Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group. by Jones RN, Marshall SA and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 103-110

Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997. by Jones RN, Kugler KC, Pfaller MA and Winokur PL published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 55-63

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. by Jones RN published in Clin. Infect. Dis. 1999; 29 (3): 495-502

The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections. by Jones RN published in Am. J. Health Syst. Pharm. 1999; 56 (22 Suppl 3): S4-S11

Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. by Jones RN, Erwin ME, Biedenbach DJ, Johnson DM and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 227-234

Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 249-252

Summation: β-lactam resistance surveillance in the Asia-Western Pacific region. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 333-338

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods. by Jones RN, Barrett MS and Pfaller MA published in Clin. Microbiol. Infect. 1999; 5 (9): 577-579

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program (1997). by Jones RN, Winokur PL, Pfaller MA, Doern GV and Barrett T published in Clin. Microbiol. Infect. 1999; 5 (8): 478-487

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. by Johnson DM, Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 87-91

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. by Johnson DM, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 291-297

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. by Hayward CL, Erwin ME, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 99-102

Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. by Erwin ME and Jones RN published in J. Clin. Microbiol. 1999; 37 (1): 279-280

Nosocomial bloodstream infections in United States hospitals: A three- year analysis. by Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN and Wenzel RP published in Clin. Infect. Dis. 1999; 29 (2): 239-244

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Doern GV, Jones RN, Pfaller MA and Kugler K published in Antimicrob. Agents Chemother. 1999; 43 (2): 385-389

Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: A report from the College of American Pathologists Microbiology Proficiency Survey Program. by Doern GV, Brueggemann AB, Pfaller MA and Jones RN published in Arch. Pathol. Lab. Med. 1999; 123 (4): 285-289

Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). by Doern GV, Jones RN, Pfaller MA, Kugler KC and Beach ML published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 65-72

Comparison of activities of broad-spectrum β-lactam compounds against 1,128 Gram-positive cocci recently isolated in cancer treatment centers. by Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (4): 940-943

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. by Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (9): 2236-2239

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer treatment centers. by Diekema DJ, Jones RN and Rolston KV published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 37-43

Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. by Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, and Beach M published in Clin. Infect. Dis. 1999; 29 (3): 595-607

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals. by Deshpande LM, Diekema DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 81-88

Colony morphology of Candida spp. as a guide to species identification. by Buschelman B, Jones RN, Pfaller MA, Koontz FP and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 89-91

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. by Biedenbach DJ, Jones RN, Lewis MT, Croco MA, and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 275-282

Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. by Biedenbach DJ, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 305-307

Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and Etest methods. by Biedenbach DJ, Croco MA, Barrett TJ and Jones RN published in Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18 (6): 428-431

In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. by Biedenbach DJ, Lewis MT and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 277-283

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305